A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 8, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Myeloproliferative Neoplasm
Interventions
DRUG

Navitoclax

Tablet; Oral

DRUG

Ruxolitinib

Tablet; Oral

DRUG

Celecoxib

Capsule; Oral

Trial Locations (42)

807

Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 215631, Kaohsiung City

1200

Cliniques Universitaires UCL Saint-Luc /ID# 225314, Woluwe-Saint-Lambert

1431

UMHAT Sveti Ivan Rilski /ID# 240077, Sofia

4002

UMHAT Sveti Georgi /ID# 240022, Plovdiv

10000

Klinicki bolnicki centar Zagreb /ID# 240140, Zagreb

11000

University Clinical Center Serbia /ID# 240674, Belgrade

13353

Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 224835, Berlin

17325

Pennsylvania Cancer Specialists Research Institute - Gettysburg /ID# 242550, Gettysburg

18057

Universitaetsmedizin Rostock /ID# 225436, Rostock

23219

Virginia Commonwealth University Medical Center Main Hospital /ID# 228169, Richmond

25123

ASST Spedali civili di Brescia /ID# 224962, Brescia

27834

Duplicate_East Carolina University Brody School of Medicine /ID# 238560, Greenville

28027

CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 226041, Madrid

31008

Clinica Universidad de Navarra - Pamplona /ID# 224839, Pamplona

31059

IUCT Oncopole /ID# 242353, Toulouse

34125

Klinikum Kassel /ID# 225440, Kassel

35340

Dokuz Eylul University Medical Faculty /ID# 239952, Izmir

40207

Norton Cancer Institute - St. Matthews /ID# 239300, Louisville

40447

China Medical University Hospital /ID# 215634, Taichung

44718

Gabrail Cancer Center Research /ID# 228924, Canton

47014

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS /ID# 224071, Meldola

68130

Nebraska Cancer Specialists - Omaha - Wright Street /ID# 242554, Omaha

75010

AP-HP - Hopital Saint-Louis /ID# 240685, Paris

79106

Universitaetsklinikum Freiburg /ID# 222791, Freiburg im Breisgau

80054

CHU Amiens-Picardie Site Sud /ID# 240792, Amiens

91010

City of Hope /ID# 239769, Duarte

92093

Moores Cancer Center at UC San Diego /ID# 229584, La Jolla

92835

Providence - St. Jude Medical Center /ID# 242558, Fullerton

90095-1678

UCLA /Id# 222784, Los Angeles

60611-2927

Northwestern University Feinberg School of Medicine /ID# 224203, Chicago

48202-2610

Duplicate_Brigitte Harris Cancer Pavilion /ID# 238686, Detroit

06189

Centre Antoine Lacassagne - Nice /ID# 242293, Nice

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Universita Cattolica /ID# 221408, Rome

247-8533

Shonan Kamakura General Hospital /ID# 224315, Kamakura-shi

589-8511

Kindai University Hospital /ID# 213241, Osakasayama-shi

565-0871

Osaka University Hospital /ID# 213235, Suita-shi

113-8431

Juntendo University Hospital /ID# 213255, Bunkyo-ku

409-3821

University of Yamanashi Hospital /ID# 229279, Chuo-shi

08907

Hospital Duran i Reynals /ID# 224007, L'Hospitalet de Llobregat

141 86

Duplicate_Karolinska University Hospital /ID# 239992, Stockholm

581 85

Linkoping University Hospital /ID# 239995, Linköping

GL53 7AN

Gloucestershire Hospitals NHS Foundation Trust /ID# 241189, Cheltenham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY